The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective.
paper
Cited
Public
Unavailable
- Authors
- Post, S G; Whitehouse, P J; Binstock, R H; Bird, T D; Eckert, S K; Farrer, L A; Fleck, L M; Gaines, A D; Juengst, E T; Karlinsky, H; Miles, S; Murray, T H; Quaid, K A; Relkin, N R; Roses, A D; St George-Hyslop, P H; Sachs, G A; Steinbock, B; Truschke, E F; Zinn, A B
- Year
- 1997
- Journal
- JAMA
- PMID
- 9052715
- DOI
- 10.1001/jama.277.10.832
OBJECTIVE: Primary caregivers should be aware of recent progress in the genetics of Alzheimer disease (AD) and of the clinical and ethical considerations raised regarding the introduction of genetic testing for purposes of disease prediction and susceptibility (risk) analysis in asymptomatic individuals and diagnosis in patients who present clinically with dementia. This statement addresses arguments for and against clinical genetic testing. PARTICIPANTS: The 20 participants were selected by the investigators (S.G.P., T.H.M., A.B.Z., and P.J.W.) to achieve balance in the areas of genetics, counseling, ethics, and public policy, and to include leadership from related consensus projects. The consensus group met twice in closed meetings and carried on extensive correspondence over 2 years (1995-1997). The project was supported by the National Human Genome Research Institute of the National Institutes of Health. EVIDENCE: All 4 involved chromosomes were discussed in group meetings against a background of information from several focus group sessions with AD-affected families. The focus groups comprised volunteers identified by the Cleveland Area Chapter of the Alzheimer's Disease and Related Disorders Association and represented a variety of ethnic populations. CONSENSUS PROCESS: The first draft was written in April 1996 by the principal investigator (S.G.P.) after the consensus group had met twice. The draft was mailed to all consensus group members 3 times over 6 months for extensive response and redrafting by the principal investigator until all members were satisfied. CONCLUSIONS: Except for autosomal dominant early-onset families, genetic testing in asymptomatic individuals is unwarranted. Use of APOE genetic testing as a diagnostic adjunct in patients already presenting with dementia may prove useful but it remains under investigation. The premature introduction of genetic testing and possible adverse consequences are to be avoided.
No figures extracted from this document.
No chunks — full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Genetic strategies to detect genes involved in alcoholism and alcohol-related traits. | 2002 | 12875045 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Interest in apolipoprotein E (<i>APOE</i>) disclosure among at-risk, cognitively unimpaired, community-dwelling Australian adults. | Rosenich E et al. | — | 2026 | → |
| Extrasynaptic NMDA receptors in acute and chronic excitotoxicity: implications for preventive treatments of ischemic stroke and late-onset Alzheimer's disease. | Yu SP et al. | — | 2023 | → |
| Personalizing Personalized Medicine: The Confluence of Pharmacogenomics, a Person's Medication Experience and Ethics. | Stratton TP et al. | — | 2023 | → |
| Public perspective on medications to delay Alzheimer's disease symptoms. | Rich MB et al. | — | 2023 | → |
| Predictive Genetic Counseling for Neurodegenerative Diseases: Past, Present, and Future. | Goldman JS | — | 2020 | → |
| Assessing the Psychological Impact of Genetic Susceptibility Testing. | Roberts JS | — | 2019 | → |
| Understanding the Amyloid Hypothesis in Alzheimer's Disease. | Paroni G et al. | — | 2019 | → |
| Understanding the genetics of APOE and TOMM40 and role of mitochondrial structure and function in clinical pharmacology of Alzheimer's disease. | Roses A et al. | — | 2016 | → |
| Intracranial aneurysms: a game of millimeters. | Amber I et al. | — | 2015 | → |
| The translational potential of research on the ethical, legal, and social implications of genomics. | Burke W et al. | — | 2015 | → |
| A case of inappropriate apolipoprotein e testing in Alzheimer's disease due to lack of an informed consent discussion. | Furman CD et al. | — | 2014 | → |
| Public beliefs and knowledge about risk and protective factors for Alzheimer's disease. | Roberts JS et al. | — | 2014 | → |
| Tract-based spatial statistics: application to mild cognitive impairment. | Wai YY et al. | — | 2014 | → |
| Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues. | Roberts JS et al. | — | 2013 | → |
| A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases. | Paulsen JS et al. | — | 2013 | → |
| Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues. | Roberts JS et al. | — | 2013 | → |
| Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease. | Wikler EM et al. | — | 2013 | → |
| New approaches to genetic counseling and testing for Alzheimer's disease and frontotemporal degeneration. | Goldman JS | — | 2012 | → |
| Attitudes of health care professionals toward pharmacogenetic testing. | Zgheib NK et al. | — | 2011 | → |
| Differences between African American and White research volunteers in their attitudes, beliefs and knowledge regarding genetic testing for Alzheimer's disease. | Akinleye I et al. | — | 2011 | → |
| Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. | Goldman JS et al. | — | 2011 | → |
| Public attitudes toward ancillary information revealed by pharmacogenetic testing under limited information conditions. | Haga SB et al. | — | 2011 | → |
| The ethics of disclosing genetic diagnosis for Alzheimer's disease: do we need a new paradigm? | Arribas-Ayllon M | — | 2011 | → |
| Using Alzheimer's disease as a model for genetic risk disclosure: implications for personal genomics. | Roberts JS et al. | — | 2011 | → |
| An epidemiologic-based survey of public attitudes towards predictive genetic testing in Russia. | Makeeva OA et al. | — | 2010 | → |
| Complex calculations: ethical issues in involving at-risk healthy individuals in dementia research. | Pierce R | — | 2010 | → |
| Debating clinical utility. | Burke W et al. | — | 2010 | → |
| Estimating and disclosing the risk of developing Alzheimer's disease: challenges, controversies and future directions. | Roberts JS et al. | — | 2010 | → |
| Experts' opinions on ethical issues of genetic research into Alzheimer's disease: results of a Delphi study in the Netherlands. | van der Vorm A et al. | — | 2010 | → |
| Impact of gene patents and licensing practices on access to genetic testing for Alzheimer disease. | Skeehan K et al. | — | 2010 | → |
| Is risk of Alzheimer disease a reason to use dietary supplements? | Dwyer J et al. | — | 2010 | → |
| Alzheimer disease in women: a clinical and genetics perspective. | Gies C et al. | — | 2009 | → |
| A new scale measuring psychologic impact of genetic susceptibility testing for Alzheimer disease. | Chung WW et al. | — | 2009 | → |
| Biomarkers, dementia, and public health. | Wright CF et al. | — | 2009 | → |
| Clinical ethics issues in geriatric psychiatry. | Walaszek A | — | 2009 | → |
| Disclosing the disclosure: factors associated with communicating the results of genetic susceptibility testing for Alzheimer's disease. | Ashida S et al. | — | 2009 | → |
| Disclosure of APOE genotype for risk of Alzheimer's disease. | Green RC et al. | — | 2009 | → |
| Genetic aspects of Alzheimer disease. | Williamson J et al. | — | 2009 | → |
| Comparing test-specific distress of susceptibility versus deterministic genetic testing for Alzheimer's disease. | Cassidy MR et al. | — | 2008 | → |
| Genetic aspects of Alzheimer disease. | Bird TD | — | 2008 | → |
| Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study. | Chao S et al. | — | 2008 | → |
| Psychiatrists' attitudes regarding genetic testing and patient safeguards: a preliminary study. | Hoop JG et al. | — | 2008 | → |
| Standard Operating Procedures, ethical and legal regulations in BTB (Brain/Tissue/Bio) banking: what is still missing? | Ravid R | — | 2008 | → |
| Standard Operating Procedures, ethical and legal regulations in BTB (Brain/Tissue/Bio) banking: what is still missing? | Ravid R | — | 2008 | → |
| Defining purpose: a key step in genetic test evaluation. | Burke W et al. | — | 2007 | → |
| Future use of genomics in coronary artery disease. | Damani SB et al. | — | 2007 | → |
| Areas of intervention for genetic counselling of dementia: cross-cultural comparison between Italians and Americans. | Binetti G et al. | — | 2006 | → |
| Context, ethics and pharmacogenetics. | Hedgecoe AM | — | 2006 | → |
| Genetic counseling in psychiatry. | Finn CT et al. | — | 2006 | → |
| The primary care of Alzheimer disease. | Rubin CD | — | 2006 | → |
| Association between apolipoprotein E polymorphism and Alzheimer disease in Tehran, Iran. | Raygani AV et al. | — | 2005 | → |
| Firing up the nature/nurture controversy: bioethics and genetic determinism. | de Melo-Martín I | — | 2005 | → |
| Genetic risk assessment for adult children of people with Alzheimer's disease: the Risk Evaluation and Education for Alzheimer's Disease (REVEAL) study. | Roberts JS et al. | — | 2005 | → |
| Genetic susceptibility for Alzheimer's disease: why did adult offspring seek testing? | Hurley AC et al. | — | 2005 | → |
| Apolipoprotein E and the risk of breast cancer in African-American and non-Hispanic white women. A review. | Moore RJ et al. | — | 2004 | → |
| Ethical issues in molecular medicine of relevance to surgeons. | Bernstein M et al. | — | 2004 | → |
| APOE epsilon4 as a predictor of subjective quality of life in a biracial older person community sample. | Blazer DG et al. | — | 2003 | → |
| Conducting research related to treatment of Alzheimer's disease. Ethical issues. | Sevick MA et al. | — | 2003 | → |
| Differences between African Americans and Whites in their attitudes toward genetic testing for Alzheimer's disease. | Hipps YG et al. | — | 2003 | → |
| "Genetic exceptionalism" in medicine: clarifying the differences between genetic and nongenetic tests. | Green MJ et al. | — | 2003 | → |
| [Genetics and Alzheimer disease]. | Codina Puiggrós A et al. | — | 2003 | → |
| Reasons for seeking genetic susceptibility testing among first-degree relatives of people with Alzheimer disease. | Roberts JS et al. | — | 2003 | → |
| The analysis of survival data with a non-susceptible fraction and dual censoring mechanisms. | Gagnon DR et al. | — | 2003 | → |
| To test or not to test: interest in genetic testing for Alzheimer's disease among middle-aged adults. | Cutler SJ et al. | — | 2003 | → |
| Genetic strategies to detect genes involved in alcoholism and alcohol-related traits. | Dick DM et al. | — | 2002 | → |
| Physicians' propensity to offer genetic testing for Alzheimer's disease: results from a survey. | Chase GA et al. | — | 2002 | → |
| Application of population screening principles to genetic screening for adult-onset conditions. | Burke W et al. | — | 2001 | → |
| Categorizing genetic tests to identify their ethical, legal, and social implications. | Burke W et al. | — | 2001 | → |
| Clinical aspects of Alzheimer's disease. | Bianchetti A et al. | — | 2001 | → |
| EFNS Task Force on Molecular Diagnosis of Neurologic Disorders: guidelines for the molecular diagnosis of inherited neurologic diseases. First of two parts. | Gasser T et al. | — | 2001 | → |
| Genetic counselling and genetic screening for Alzheimer's disease and other dementias. | Sadovnick AD | — | 2001 | → |
| Preventing schizophrenia and Alzheimer disease: comparative ethics. | Post SG | — | 2001 | → |
| Public attitudes about genetic testing for Alzheimer's disease. | Neumann PJ et al. | — | 2001 | → |
| The challenge of integrating genetic medicine into primary care. | Emery J et al. | — | 2001 | → |
| The complexities of predictive genetic testing. | Evans JP et al. | — | 2001 | → |
| The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. | Patterson C et al. | — | 2001 | → |
| Apolipoprotein E genotyping for pharmacogenetic purposes in Alzheimer's disease: emerging ethical issues. | Issa AM et al. | — | 2000 | → |
| Commercial predictive testing: the desirability of one overseeing body. | Hoedemaekers R | — | 2000 | → |
| Current and future clinical trials for Alzheimer's disease: evolving ethical concerns. | Issa AM et al. | — | 2000 | → |
| Ethics in the laboratory examination of patients. | Nyrhinen T et al. | — | 2000 | → |
| Genetic testing for Alzheimer's disease. | Panegyres PK et al. | — | 2000 | → |
| Genetic testing in children: ethical and social points to consider. | Hanson JW et al. | — | 2000 | → |
| Key issues in the ethics of dementia care. | Post SG | — | 2000 | → |
| New insights into genetic aspects of Alzheimer's disease. Does genetic information make a difference in clinical practice? | Blacker D | — | 2000 | → |
| On the use of population-based registries in the clinical validation of genetic tests for disease susceptibility. | Yang Q et al. | — | 2000 | → |
| Part V. Genetic advances and biological markers for Alzheimer's disease. | Galasko DR | — | 2000 | → |
| Evaluation of genetic tests: APOE genotyping for the diagnosis of Alzheimer disease. | McConnell LM et al. | — | 1999 | → |
| Genetic services for common complex disorders: surveys of health maintenance organizations and academic genetic centers. | Myers MF et al. | — | 1999 | → |
| Genetic testing and Alzheimer disease: recommendations of the Stanford Program in Genomics, Ethics, and Society. | McConnell LM et al. | — | 1999 | → |
| Initial evaluation of suspected dementia. Asking the right questions. | Steffens DC et al. | — | 1999 | → |
| Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers. | González C et al. | — | 1999 | → |
| The genetics of Alzheimer disease and the application of molecular tests. | Tobin SL et al. | — | 1999 | → |
| Advances and challenges in the prevention and treatment of Alzheimer's disease. | Diaz Brinton R et al. | — | 1998 | → |
| Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease. | Lasser RA et al. | — | 1998 | → |
| Apolipoprotein E phenotypes, dementia and mortality in a prospective population sample. | Tilvis RS et al. | — | 1998 | → |
| Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s. | Berchtold NC et al. | — | 1998 | → |
| Genetic testing and Alzheimer disease: has the time come? Alzheimer Disease Working Group of the Stanford Program in Genomics, Ethics & Society. | McConnell LM et al. | — | 1998 | → |
| Genetic testing in Alzheimer's disease. Benefits risks and public policy. | Schutte DL | — | 1998 | → |
| Molecular genetics of familial Alzheimer disease. | Shastry BS | — | 1998 | → |
| Progress in the management of Alzheimer's disease. | Smith AL et al. | — | 1998 | → |
| Role of genetics in tests of genotype, status, and disease progression in early-onset Alzheimer's disease. | St George-Hyslop PH | — | 1998 | → |
| The impact of Alzheimer disease genetics on expert and advanced gerontological nursing practice. | Schutte DL | — | 1998 | → |
| The 'research magnificent' in late life: psychiatric epidemiology and the primary health care of older adults. | Gallo JJ et al. | — | 1997 | → |